Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis
Conor Driscoll, Jordan Rich, Dylan Isaacson, Joseph Nicolas, Yu Jiang, Xinlei Mi, Christopher C. Yang, Victoria Kocsuta, Regine Goh, Niti G. Patel, Eric Li, Mohammad Rashid Siddiqui, Travis J. Meyers, John S. Witte, Linda Kachuri, Hui Zhang, Molly Beestrum, Philip Silberman, Edward M. Schaeffer, Shilajit Kundu
Abstract
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].
Topics & Concepts
Tumor necrosis factor alphaMedicineMalignancyMeta-analysisTumor necrosis factor αInternal medicineOncologyInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis